The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...
For the first time in 20 years, the Food and Drug Administration has approved a new pharmaceutical approach to treating pain.
If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...
The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...
SALT LAKE CITY, UTAH / ACCESS Newswire / February 6, 2025 /CenExel, a leading network of clinical research sites, proudly ...
The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a ...
The Food and Drug Administration (FDA) has approved Journavxâ„¢ (suzetrigine) for the treatment of moderate to severe acute pain in adults.
Vertex has gained the FDA's approval for its nonaddictive pain med Journavx, which becomes the first significant innovation ...
One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which ...
The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.